Literature DB >> 16109351

Ipecac syrup abuse, morbidity, and mortality: isn't it time to repeal its over-the-counter status?

Tomas J Silber1.   

Abstract

PURPOSE: To review and address the abuse of ipecac, describing its epidemiology, toxicity, clinical characteristics, and laboratory assessment.
METHODS: A Medline search (1980-2003) for Ipecac abuse and Ipecac toxicity, n = 34.
RESULTS: Ipecac abuse occurs predominantly among adolescent and young adult females who are either experimenting with purging or have an eating disorder. Psychiatric comorbidity is common. Death can occur and is usually of cardiac origin. Morbidity includes myocarditis with arrhythmias, myositis, gastroesophageal pathology, including Mallory Weiss tears, diarrhea, and metabolic abnormalities (alkalosis, hypokalemia, dehydration). The injuries can reverse with cessation of ipecac use. A high index of suspicion is needed for early detection. Classic findings are abnormal EKG and echocardiography and/or elevation of muscle enzymes (CPK, adolase). Emetine, the alkaloid in ipecac, can be confirmed in serum, urine, and tissue by high performance liquid chromatography.
CONCLUSIONS: Ipecac abuse is dangerous, even deadly. However, if abuse is discontinued, cardiac and muscle damage tends to reverse. Were ipecac syrup to remain an over- the-counter medication, or become a prescription medication, more stringent warning labels ought to be included and further education be provided about its toxicity and potential for abuse. Removing ipecac from the over-the-counter category would best eliminate its potential for abuse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109351     DOI: 10.1016/j.jadohealth.2004.08.022

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  7 in total

Review 1.  The medical complications associated with purging.

Authors:  K Jean Forney; Jennifer M Buchman-Schmitt; Pamela K Keel; Guido K W Frank
Journal:  Int J Eat Disord       Date:  2016-02-15       Impact factor: 4.861

2.  A latent profile analysis of the typology of bulimic symptoms in an indigenous Pacific population: evidence of cross-cultural variation in phenomenology.

Authors:  J J Thomas; R D Crosby; S A Wonderlich; R H Striegel-Moore; A E Becker
Journal:  Psychol Med       Date:  2010-03-29       Impact factor: 7.723

Review 3.  Over-the-counter and out-of-control: legal strategies to protect youths from abusing products for weight control.

Authors:  Jennifer L Pomeranz; Lisa M Taylor; S Bryn Austin
Journal:  Am J Public Health       Date:  2012-12-13       Impact factor: 9.308

4.  Medical complications of bulimia nervosa and their treatments.

Authors:  Katherine Sachs; Philip S Mehler
Journal:  Eat Weight Disord       Date:  2015-07-14       Impact factor: 4.652

5.  Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.

Authors:  D Tricarico; S Lovaglio; A Mele; G Rotondo; E Mancinelli; G Meola; D C Camerino
Journal:  Br J Pharmacol       Date:  2008-03-17       Impact factor: 8.739

Review 6.  Sudden death in eating disorders.

Authors:  Beatriz Jáuregui-Garrido; Ignacio Jáuregui-Lobera
Journal:  Vasc Health Risk Manag       Date:  2012-02-15

7.  The current status of suicide and self-injury in eating disorders: a narrative review.

Authors:  Katrina Kostro; Jessica B Lerman; Evelyn Attia
Journal:  J Eat Disord       Date:  2014-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.